Search results
Results from the WOW.Com Content Network
CimaVax-EGF is a vaccine used to treat cancer, specifically non-small-cell lung carcinoma (NSCLC). CIMAvax-EGF is composed of recombinant human epidermal growth factor (EGF) conjugated to a protein carrier. [2] The vaccine was developed by the Center of Molecular Immunology, Havana, Cuba, and made available to the Cuban population in 2011.
A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. [1] Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines .
According to the U.S. Centers for Disease Control and Prevention, while "any vaccine can cause side effects", [11] most side effects are minor, primarily including sore arms or a mild fever. [11] Unlike most medical interventions vaccines are given to healthy people, where the risk of side effects is not as easily outweighed by the benefit of ...
A student athlete was diagnosed with myocarditis after ... who acknowledge that vaccines can have any potential side effects, stress that these rare reactions must be weighed against the realities ...
The study only documented myocarditis and pericarditis, rare inflammatory heart conditions, in the vaccinated group, but the incidences were very rare − 27 cases per million after the first dose ...
About 75% of the patients on the vaccine combination had recurrence-free survival, compared with 55.6% on Keytruda alone. Moderna-Merck skin cancer vaccine shows survival benefit in long-term ...
Myocarditis and pericarditis can be a side effect of some vaccines like the smallpox vaccine. [30] Myocarditis can be a side-effect of the Covid-19 mRNA vaccines. The FDA and European Medicines Agency estimates the risk of myocarditis after the Covid-19 vaccine as 1 case per 100,000 of those who are vaccinated.
VAERS is a postmarketing surveillance program, collecting information about adverse events (possible harmful side effects) that occur after administration of vaccines to ascertain whether the risk–benefit ratio is high enough to justify continued use of any particular vaccine.